The SKIPPirr Study: Dr. Spira Shares Insights at IASLC 2024 World Conference on Lung Cancer

Alexander Spira, MD, PhD, FACP, FASCO, of Virginia Cancer Specialists, discussese the phase 2 SKIPPirr study results presented by Gilberto Lopes, MD, during the IASLC 2024 World Conference on Lung Cancer.

The global SKIPPirr study evaluated the use of prophylaxis in patients receiving oral lazertinib and intravenous amivantamab, as intravenous amivantamab has an infusion-related reaction incidence of around 67%, typically at the first infusion, according to investigators.

“The SKIPPirr study is a study looking at how we mitigate some of the infusion reactions from amivantamab,” Dr. Spira said.

The study enrolled patients with EGFR-mutated (Ex19del or L858R) advanced non-small cell lung cancer after disease progression on sequential osimertinib and platinum-based chemotherapy.

“This is a very straightforward study that looked at a couple of different ways to help mitigate those reactions,” Dr. Spira said. “One of which was giving dexamethasone premedication, one of which was giving methotrexate, and another was giving montelukast, the asthma and allergy drug.”

The study evaluated these strategies in 4 cohorts using Simon’s 2-stage design strategy.

“I know this sounds very simple, but steroids actually helped,” Dr. Spira said.

Specifically, the study showed that prophylaxis with 8-mg oral dexamethasone “resulted in a meaningful reduction” in the infusion-related reaction incidence, according to the study authors.

“Giving patients dexamethasone at relatively modest doses can actually mitigate a lot of these infusion-related reactions,” Dr. Spira said. “This will be very helpful for our patients as they get this formulation going forward.”